Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $5.00 Average Price Target from Brokerages

Gossamer Bio, Inc. (NASDAQ:GOSS) has received a consensus recommendation of “Hold” from the ten analysts that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $5.00.

GOSS has been the topic of several research reports. Leerink Partners downgraded shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Barclays downgraded shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a report on Tuesday, February 24th. Wedbush reiterated a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a report on Tuesday, February 24th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Gossamer Bio in a report on Monday, March 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Gossamer Bio in a report on Tuesday, May 26th.

Institutional Investors Weigh In On Gossamer Bio

Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc purchased a new stake in Gossamer Bio in the 2nd quarter worth approximately $26,000. Banco BTG Pactual S.A. purchased a new stake in Gossamer Bio in the 2nd quarter worth approximately $27,000. MMA Asset Management LLC purchased a new stake in Gossamer Bio in the 4th quarter worth approximately $31,000. Soltis Investment Advisors LLC purchased a new stake in Gossamer Bio in the 4th quarter worth approximately $31,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in Gossamer Bio in the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Trading Up 0.4%

Shares of NASDAQ:GOSS opened at $0.17 on Friday. Gossamer Bio has a twelve month low of $0.14 and a twelve month high of $3.87. The company’s 50 day moving average is $0.29 and its 200 day moving average is $1.44. The company has a market cap of $39.36 million, a PE ratio of -0.21 and a beta of 2.00.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $16.96 million for the quarter, compared to the consensus estimate of $4.67 million. Equities research analysts predict that Gossamer Bio will post -0.45 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.